stockrowPenumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
Follow PEN
Alert me
Penumbra, Inc. (PEN) EBITDA
Penumbra, Inc.'s EBITDA for fiscal 2025 was $206.7M, up 526.8% from $33.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $209.4M. Over the past ten years it has ranged from −$23.6M (fiscal 2020) to $206.7M (fiscal 2025) — the current reading is the highest in ten years. Penumbra, Inc. ranks 23rd of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $206.7M | 526.78% |
| FY2024 | $33.0M | (67.28%) |
| FY2023 | $100.8M | 231.57% |
| FY2022 | $30.4M | 241.34% |
| FY2021 | $8.9M | — |
| FY2020 | −$23.6M | — |
| FY2019 | $55.6M | 946.12% |
| FY2018 | $5.3M | 7.48% |
| FY2017 | $4.9M | 154.42% |
| FY2016 | $1.9M | (67.68%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $56.2M | 20.47% |
| Jun 2026 | $46.7M | 8.98% |
| Mar 2026 | $42.8M | (32.79%) |
| Dec 2025 | $63.7M | 24.10% |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.6B |
| GMED Globus Medical, Inc. compare | $932.9M |
| PODD Insulet Corporation compare | $693.3M |
| PEN Penumbra, Inc. | $209.4M |
| BRKR Bruker Corporation compare | $158.7M |
| TXG 10x Genomics compare | −$40.4M |
| BIO.B Bio-Rad Laboratories, Inc. compare | −$61.9M |
| BIO Bio-Rad Laboratories, Inc. compare | −$61.9M |
| GKOS Glaukos Corporation compare | −$130.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on PEN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement